肥胖与早期乳腺癌预后和辅助治疗疗效的研究进展

doi:10.16139/j.1007-9610.2022.05.017

摘要/Abstract

摘要：

全球超重和肥胖人口逐年增加，乳腺癌病人体质量指数与预后和疗效的关系成为研究热点。本文综述肥胖对早期乳腺癌预后和辅助治疗疗效的影响。研究表明，体质量指数高与肿瘤大、淋巴结转移多以及组织学分级高和增殖指数高相联系。肥胖对不同亚型早期乳腺癌预后的影响不同。激素受体阳性的乳腺癌病人中，肥胖者预后较差。肥胖与其他亚型预后的关系尚存争议。在早期乳腺癌药物治疗反应方面，肥胖可能会降低亲脂性辅助化疗药物的疗效。肥胖对辅助内分泌治疗疗效的影响可能与芳香化酶抑制剂的种类相关。肥胖与辅助抗HER2靶向治疗疗效的关系尚不明确。

关键词: 乳腺癌, 肥胖, 辅助治疗

Abstract:

With overweight and obese population increasing worldwide, the association of body mass index(BMI) of breast cancer patients with the prognosis and treatment efficacy has become a hot topic. Here we reviewed the impact of obesity on prognosis and efficacy of adjuvant therapy of early breast cancer. A number of studies have shown that higher BMI was associated with larger tumors and increased lymph node involvement, more grading and higher proliferation. The effect of obesity on prognosis of early breast cancer differed across disease subtypes. Obesity was associated with poorer prognosis for hormone receptor-positive breast cancer, while the association of obesity with prognosis for other breast cancer subtypes was still controversial. Obesity could probably decrease the efficacy of adjuvant lipophilic chemotherapies for early breast cancer. The impact of obesity on efficacy of adjuvant endocrine therapy might depend on the type of aromatase inhibitor. The correlation between obesity and efficacy of adjuvant HER2- targeted therapy has not been clear.

Key words: Breast cancer, Obesity, Adjuvant therapy

中图分类号:

R737.9

朱思毅综述, 陈小松, 沈坤炜审校. 肥胖与早期乳腺癌预后和辅助治疗疗效的研究进展[J]. 外科理论与实践, 2022, 27(05): 468-472.

ZHU Siyi, CHEN Xiaosong, SHEN Kunwei. Study on obesity associated with prognosis of early breast cancer and efficacy of adjuvant therapy[J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 468-472.

参考文献 40

[1]	World Cancer Research Fund. Body fatness and weight gain and the risk of cancer[EB/OL]. ( 2021-01-21) [2021-05-14]. .
[2]	Desmedt C, Fornili M, Clatot F, et al. Differential benefit of adjuvant docetaxel-based chemotherapy in patients with early breast cancer according to baseline body mass index[J]. J Clin Oncol, 2020, 38(25):2883-2891.
[3]	Crozier JA, Moreno-Aspitia A, Ballman KV, et al. Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831[J]. Cancer, 2013, 119(13):2447-2454.
[4]	Jiralerspong S, Kim ES, Dong W, et al. Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients[J]. Ann Oncol, 2013, 24(10):2506-2514.
[5]	Copson ER, Cutress RI, Maishman T, et al. Obesity and the outcome of young breast cancer patients in the UK: the POSH study[J]. Ann Oncol, 2015, 26(1):101-112.
[6]	Widschwendter P, Friedl TW, Schwentner L, et al. The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial[J]. Breast Cancer Res, 2015, 17(1):129.
[7]	Pajares B, Pollán M, Martín M, et al. Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis[J]. Breast Cancer Res, 2013, 15(6):R105.
[8]	Sparano JA, Wang M, Zhao F, et al. Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer[J]. Cancer, 2012, 118(23):5937-5946.
[9]	Ewertz M, Gray KP, Regan MM, et al. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial[J]. J Clin Oncol, 2012, 30(32):3967-3975.
[10]	Wang J, Cai Y, Yu F, et al. Body mass index increases the lymph node metastasis risk of breast cancer: a dose-response meta-analysis with 52904 subjects from 20 cohort studies[J]. BMC Cancer, 2020, 20(1):601.
[11]	Daling JR, Malone KE, Doody DR, et al. Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma[J]. Cancer, 2001, 92(4):720-729.
[12]	Torres-de la Roche LA, Steljes I, Janni W, et al. The association between obesity and premenopausal breast cancer according to intrinsic subtypes-a systematic review[J]. Geburtshilfe Frauenheilkd, 2020, 80(6):601-610.
[13]	Kwan ML, Kroenke CH, Sweeney C, et al. Association of high obesity with PAM50 breast cancer intrinsic subtypes and gene expression[J]. BMC Cancer, 2015, 15:278.
[14]	Bergom C, Kelly T, Bedi M, et al. Association of locoregional control with high body mass index in women undergoing breast conservation therapy for early-stage breast cancer[J]. Int J Radiat Oncol Biol Phys, 2016, 96(1):65-71.
[15]	Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults[J]. N Engl J Med, 2003, 348(17):1625-1638.
[16]	Chan DSM, Vieira AR, Aune D, et al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies[J]. Ann Oncol, 2014, 25(10):1901-1914.
[17]	Jeon YW, Kang SH, Park MH, et al. Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival[J]. BMC Cancer, 2015, 15:865.
[18]	Nechuta S, Chen WY, Cai H, et al. A pooled analysis of post-diagnosis lifestyle factors in association with late estrogen-receptor-positive breast cancer prognosis[J]. Int J Cancer, 2016, 138(9):2088-2097.
[19]	Wolters R, Schwentner L, Regierer A, et al. Endocrine therapy in obese patients with primary breast cancer: another piece of evidence in an unfinished puzzle[J]. Breast Cancer Res Treat, 2012, 131(3):925-931.
[20]	Cespedes Feliciano EM, Kwan ML, Kushi LH, et al. Body mass index, PAM50 subtype, recurrence, and survival among patients with nonmetastatic breast cancer[J]. Cancer, 2017, 123(13):2535-2542.
[21]	Ligibel JA, Cirrincione CT, Liu M, et al. Body mass index, PAM50 subtype, and outcomes in node-positive breast cancer: CALGB 9741(Alliance)[J]. J Natl Cancer Inst, 2015, 107(9):djv179.
[22]	Picon-Ruiz M, Morata-Tarifa C, Valle-Goffin JJ, et al. Obesity and adverse breast cancer risk and outcome: mechanistic insights and strategies for intervention[J]. CA Cancer J Clin, 2017, 67(5):378-397.
[23]	Ballinger TJ, Jiang G, Kassem N, et al. Impact of body mass index on presence of ctDNA and disease recurrence after neoadjuvant chemotherapy for triple-negative breast cancer: analysis from BRE12-158[J]. Clin Cancer Res, 2021, 27(4):1195-1199.
[24]	Lohmann AE, Soldera SV, Pimentel I, et al. Association of obesity with breast cancer outcome in relation to cancer subtypes: a meta-analysis[J]. J Natl Cancer Inst, 2021, 113(11):1465-1475.
[25]	Choi Y, Park SK, Ahn KJ, et al. Being overweight or obese increases the risk of progression in triple-negative breast cancer after surgical resection[J]. J Korean Med Sci, 2016, 31(6):886-891.
[26]	Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene[J]. Science, 1987, 235(4785):177-182.
[27]	Mazzarella L, Disalvatore D, Bagnardi V, et al. Obesity increases the incidence of distant metastases in oestrogen receptor-negative human epidermal growth factor receptor 2-positive breast cancer patients[J]. Eur J Cancer, 2013, 49(17):3588-3597.
[28]	Cantini L, Pistelli M, Merloni F, et al. Body mass index and hormone receptor status influence recurrence risk in HER2-positive early breast cancer patients[J]. Clin Breast Cancer, 2020, 20(1):e89-e98.
[29]	Martel S, Lambertini M, Agbor-Tarh D, et al. Body mass index and weight change in patients with HER2-positive early breast cancer: exploratory analysis of the ALTTO BIG 2-06 Trial[J]. J Natl Compr Canc Netw, 2021, 19(2):181-189.
[30]	Cecchini RS, Swain SM, Costantino JP, et al. Body mass index at diagnosis and breast cancer survival prognosis in clinical trial populations from NRG oncology/NSABP B-30, B-31, B-34, and B-38[J]. Cancer Epidemiol Biomar-kers Prev, 2016, 25(1):51-59.
[31]	Yerushalmi R, Dong B, Chapman JW, et al. Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials[J]. Ann Oncol, 2017, 28(7):1560-1568.
[32]	Tong Y, Wu J, Huang O, et al. IGF-1 interacted with obesity in prognosis prediction in HER2-positive breast cancer patients[J]. Front Oncol, 2020, 10:550.
[33]	Jiralerspong S, Goodwin PJ. Obesity and breast cancer prognosis: evidence, challenges, and opportunities[J]. J Clin Oncol, 2016, 34(35):4203-4216.
[34]	Berclaz G, Li S, Price KN, et al. Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience[J]. Ann Oncol, 2004, 15(6):875-884.
[35]	de Azambuja E, McCaskill-Stevens W, Francis P, et al. The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial[J]. Breast Cancer Res Treat, 2010, 119(1):145-153.
[36]	Sparreboom A, Wolff AC, Mathijssen RH, et al. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese[J]. J Clin Oncol, 2007, 25(30):4707-4713.
[37]	Pfeiler G, Königsberg R, Fesl C, et al. Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial[J]. J Clin Oncol, 2011, 29(19):2653-2659.
[38]	Sestak I, Distler W, Forbes JF, et al. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial[J]. J Clin Oncol, 2010, 28(21):3411-3415.
[39]	Seynaeve C, Hille E, Hasenburg A, et al. The impact of body mass index(BMI) on the efficacy of adjuvant endocrine therapy in postmenopausal hormone sensitive breast cancer(BC) patients[J]. Cancer Res, 2010, 70( < W>24 Suppl):Abstract nr S2-3.
[40]	Sendur MA, Aksoy S, Zengin N, et al. Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index[J]. Br J Cancer, 2012, 107(11):1815-1819.